Developing Aptamer–siRNA Conjugates for Targeted Delivery to Muscle Moving Beyond Antibody Conjugates
9:30 am - Thursday 28th January 2027
- Repurposing transferrin receptor 1 (TfR1)-binding aptamers as targeting ligands for systemic siRNA delivery
- Demonstrating selective and durable siRNA activity in skeletal muscle following a single systemic dose
- Establishing aptamer–siRNA conjugates as a promising platform for next-generation targeted oligonucleotide therapeutics
New Data
